{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+3A&page=2",
    "query": {
      "intervention": "Cohort 3A",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+3A&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T07:17:11.708Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04095273",
      "title": "Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Elimusertib (BAY1895344)",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (Keytruda®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2019-09-30",
      "completion_date": "2023-04-11",
      "has_results": false,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-09-28T07:17:11.708Z",
      "location_count": 8,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04095273"
    },
    {
      "nct_id": "NCT01984229",
      "title": "A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Posaconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 23,
      "start_date": "2013-12",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2016-10-11",
      "last_synced_at": "2026-09-28T07:17:11.708Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01984229"
    },
    {
      "nct_id": "NCT01660607",
      "title": "Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myeloid Leukemia, Chronic",
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndromes (MDS)",
        "Lymphoma, Non-Hodgkin",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Myeloproliferative Syndrome",
        "Acute Myeloid Leukemia",
        "Acute Leukemia",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "CD34+ Hematopoietic Progenitor Cells (HSPC)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Regulatory T-Cells (Treg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Conventional T-Cells (Tcon)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Myeloablative Conditioning Regimen",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "73 Years",
        "sex": "ALL",
        "summary": "13 Years to 73 Years"
      },
      "enrollment_count": 68,
      "start_date": "2012-02-09",
      "completion_date": "2023-12-20",
      "has_results": true,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-09-28T07:17:11.708Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01660607"
    },
    {
      "nct_id": "NCT06576843",
      "title": "INDV-6001 Multiple-Dose Pharmacokinetic Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Moderate to Severe Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "INDV-6001",
          "type": "DRUG"
        },
        {
          "name": "Suboxone",
          "type": "DRUG"
        },
        {
          "name": "Sublocade",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indivior Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 123,
      "start_date": "2024-09-17",
      "completion_date": "2026-01-21",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-09-28T07:17:11.708Z",
      "location_count": 11,
      "location_summary": "San Diego, California • Miami Lakes, Florida • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Flowood",
          "state": "Mississippi"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06576843"
    },
    {
      "nct_id": "NCT05440942",
      "title": "Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Retifanlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peter Hosein, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2023-01-19",
      "completion_date": "2025-05-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-09-28T07:17:11.708Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05440942"
    },
    {
      "nct_id": "NCT04923126",
      "title": "SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Low-Grade Glioma",
        "Recurrent Low-Grade Glioma",
        "Progressive Low-Grade Glioma"
      ],
      "interventions": [
        {
          "name": "Mirdametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "2 Years to 24 Years"
      },
      "enrollment_count": 132,
      "start_date": "2021-06-21",
      "completion_date": "2031-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-28T07:17:11.708Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04923126"
    },
    {
      "nct_id": "NCT04464798",
      "title": "A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "CC-220",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2020-11-11",
      "completion_date": "2025-01-09",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-09-28T07:17:11.708Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Lake Mary, Florida • Rochester, Minnesota + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04464798"
    },
    {
      "nct_id": "NCT01805024",
      "title": "Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Congenital Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Omigapil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santhera Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "5 Years to 16 Years"
      },
      "enrollment_count": 20,
      "start_date": "2014-12",
      "completion_date": "2018-01-29",
      "has_results": true,
      "last_update_posted_date": "2021-09-24",
      "last_synced_at": "2026-09-28T07:17:11.708Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01805024"
    },
    {
      "nct_id": "NCT01476137",
      "title": "A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "GSK1120212",
          "type": "DRUG"
        },
        {
          "name": "GSK2110183",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 335,
      "start_date": "2011-10-26",
      "completion_date": "2013-03-12",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-09-28T07:17:11.708Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01476137"
    },
    {
      "nct_id": "NCT05285137",
      "title": "Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "CD388 Injection",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Saline placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 77,
      "start_date": "2022-03-14",
      "completion_date": "2023-10-27",
      "has_results": true,
      "last_update_posted_date": "2025-02-27",
      "last_synced_at": "2026-09-28T07:17:11.708Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05285137"
    }
  ]
}